Compounds and compositions and uses thereof

Patent metadata

Field	Value
Publication number	US-11077090-B2
Application number	US-201715663672-A
Country	US
Kind code	B2
Filing date	Jul 28, 2017
Priority date	Jul 29, 2016
Publication date	Aug 3, 2021
Grant date	Aug 3, 2021

Abstract

Compounds of formula I:are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric diseases and disorders in a subject in need thereof are also disclosed.

First claim

The invention claimed is:

1. A composition comprising a compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof, and wherein said composition is greater than 90% enantiomerically pure.

2. The composition according to claim 1 , wherein said composition is greater than 95% enantiomerically pure.

3. A composition comprising a compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof, and wherein said composition is greater than 90% enantiomerically pure.

4. The composition according to claim 3 , wherein said composition is greater than 95% enantiomerically pure.

5. A pharmaceutical composition comprising a compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

6. A pharmaceutical composition comprising a compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

7. The pharmaceutical composition of claim 6 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

8. The pharmaceutical composition of claim 5 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

9. The pharmaceutical composition of claim 5 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

10. The pharmaceutical composition of claim 5 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

11. The pharmaceutical composition of claim 5 , wherein said compound is:

or a pharmaceutically acceptable salt thereof.

12. A method for alleviating or inhibiting the progress of a neurological or psychiatric disease or disorder selected from the group consisting of depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, a movement disorder, epilepsy, Alzheimer's disease, Parkinson's disease, autism and cognitive impairments in a subject in need thereof, comprising administering to said subject an effective amount of a compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof.

13. The method of claim 12 , wherein said neurological or psychiatric disorder is depression.

14. The method of claim 13 , wherein the depression is treatment-resistant depression (TRD), major depressive disorder (MDD), unipolar depression, bipolar depression or depression associated with another disease or disorder.

15. The method of claim 12 , wherein said neurological or psychiatric disorder is bipolar disorder.

16. The method of claim 12 , wherein said neurological or psychiatric disorder is pain.

17. The method of claim 12 , wherein said neurological or psychiatric disorder is schizophrenia.

18. The method of claim 12 , wherein said neurological or psychiatric disorder is obsessive compulsive disorder.

19. The method of claim 12 , wherein said neurological or psychiatric disorder is addiction.

20. The method of claim 12 , wherein said neurological or psychiatric disorder is social disorder.

21. The method of claim 12 , wherein said neurological or psychiatric disorder is attention deficit hyperactivity disorder.

22. The method of claim 12 , wherein said neurological or psychiatric disorder is an anxiety disorder.

23. The method of claim 12 , wherein said neurological or psychiatric disorder is a movement disorder.

24. The method of claim 12 , wherein said neurological or psychiatric disorder is Alzheimer's disease.

25. The method of claim 12 , wherein said neurological or psychiatric disorder is Parkinson's disease.

26. The method of claim 12 , wherein said neurological or psychiatric disorder is autism.

27. The method of claim 12 , wherein said neurological or psychiatric disorder is cognitive impairments.

28. A method of alleviating or inhibiting the progress of a neurological or psychiatric disease or disorder selected from the group consisting of depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, a movement disorder, epilepsy, Alzheimer's disease, Parkinson's disease, autism and cognitive impairments in a subject in need thereof, comprising administering to said subject an effective amount of a compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof.

29. The method of claim 28 , wherein said neurological or psychiatric disorder is depression.

30. The method of claim 29 , wherein the depression is treatment-resistant depression (TRD), major depressive disorder (MDD), unipolar depression, bipolar depression or depression associated with another disease or disorder.

31. The method of claim 28 , wherein said neurological or psychiatric disorder is bipolar disorder.

32. The method of claim 28 , wherein said neurological or psychiatric disorder is pain.

33. The method of claim 28 , wherein said neurological or psychiatric disorder is schizophrenia.

34. The method of claim 28 , wherein said neurological or psychiatric disorder is obsessive compulsive disorder.

35. The method of claim 28 , wherein said neurological or psychiatric disorder is addiction.

36. The method of claim 28 , wherein said neurological or psychiatric disorder is social disorder.

37. The method of claim 28 , wherein said neurological or psychiatric disorder is attention deficit hyperactivity disorder.

38. The method of claim 28 , wherein said neurological or psychiatric disorder is an anxiety disorder.

39. The method of claim 28 , wherein said neurological or psychiatric disorder is a movement disorder.

40. The method of claim 28 , wherein said neurological or psychiatric disorder is Alzheimer's disease.

41. The method of claim 28 , wherein said neurological or psychiatric disorder is Parkinson's disease.

Assignees

• Sunovion Pharmaceuticals Inc
• Pgi Drug Discovery Llc

Inventors

• Alexandrov Vadim
• Bowen Carrie A
• Hanania Taleen G
• Powell Noel Aaron

Classifications

• C07D311/76 Primary

  Benzo[c]pyrans · CPC title

• C07D313/08

  condensed with one six-membered ring · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61K31/353 Primary

  3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title